Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) – Research analysts at Oppenheimer issued their Q1 2018 earnings per share estimates for shares of Eiger Biopharmaceuticals in a research note issued to investors on Monday. Oppenheimer analyst J. Olson forecasts that the biotechnology company will post earnings of ($1.06) per share for the quarter. Oppenheimer currently has a “Buy” rating and a $26.00 target price on the stock. Oppenheimer also issued estimates for Eiger Biopharmaceuticals’ Q2 2018 earnings at ($0.98) EPS, Q3 2018 earnings at ($0.96) EPS and Q4 2018 earnings at ($0.88) EPS.
A number of other equities research analysts also recently weighed in on EIGR. ValuEngine upgraded shares of Eiger Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, November 14th. Zacks Investment Research downgraded shares of Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, February 20th. Piper Jaffray Companies reiterated an “overweight” rating and set a $17.00 price target (down previously from $35.00) on shares of Eiger Biopharmaceuticals in a research note on Tuesday, January 16th. Finally, Ladenburg Thalmann Financial Services assumed coverage on shares of Eiger Biopharmaceuticals in a research note on Wednesday, January 3rd. They set a “buy” rating and a $32.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. Eiger Biopharmaceuticals presently has an average rating of “Buy” and an average target price of $27.25.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.02) by ($0.09).
Hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its holdings in shares of Eiger Biopharmaceuticals by 295.8% during the third quarter. JPMorgan Chase & Co. now owns 11,705 shares of the biotechnology company’s stock valued at $126,000 after acquiring an additional 8,748 shares during the period. OxFORD Asset Management LLP bought a new position in shares of Eiger Biopharmaceuticals during the third quarter valued at $147,000. Goldman Sachs Group Inc. bought a new position in shares of Eiger Biopharmaceuticals during the second quarter valued at $272,000. Unterberg Capital LLC bought a new position in shares of Eiger Biopharmaceuticals during the fourth quarter valued at $698,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Eiger Biopharmaceuticals by 22.8% during the fourth quarter. Renaissance Technologies LLC now owns 97,013 shares of the biotechnology company’s stock valued at $1,353,000 after acquiring an additional 18,000 shares during the period. 69.03% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/03/14/research-analysts-issue-forecasts-for-eiger-biopharmaceuticals-incs-q1-2018-earnings-eigr.html.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.